Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Identifieur interne : 000617 ( Main/Exploration ); précédent : 000616; suivant : 000618Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Auteurs : A. Vila-C Rcoles [Espagne] ; O. Ochoa-Gondar ; C. Llor ; I. Hospital ; T. Rodríguez ; A. G MezSource :
- The European respiratory journal [ 0903-1936 ] ; 2005.
Descripteurs français
- KwdFr :
- Analyse de survie (MeSH), Analyse de variance (MeSH), Espagne (épidémiologie), Facteurs âges (MeSH), Femelle (MeSH), Humains (MeSH), Indice de gravité de la maladie (MeSH), Infections communautaires (mortalité), Infections communautaires (prévention et contrôle), Modèles des risques proportionnels (MeSH), Mâle (MeSH), Pneumonie à pneumocoques (mortalité), Pneumonie à pneumocoques (prévention et contrôle), Prévalence (MeSH), Prévention primaire (méthodes), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccination (méthodes), Vaccins antipneumococciques (administration et posologie), Études de cohortes (MeSH), Études prospectives (MeSH), Évaluation gériatrique (MeSH).
- MESH :
- administration et posologie : Vaccins antipneumococciques.
- mortalité : Infections communautaires, Pneumonie à pneumocoques.
- méthodes : Prévention primaire, Vaccination.
- prévention et contrôle : Infections communautaires, Pneumonie à pneumocoques.
- épidémiologie : Espagne.
- Analyse de survie, Analyse de variance, Facteurs âges, Femelle, Humains, Indice de gravité de la maladie, Modèles des risques proportionnels, Mâle, Prévalence, Sujet âgé, Sujet âgé de 80 ans ou plus, Études de cohortes, Études prospectives, Évaluation gériatrique.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Age Factors (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Analysis of Variance (MeSH), Cohort Studies (MeSH), Community-Acquired Infections (mortality), Community-Acquired Infections (prevention & control), Female (MeSH), Geriatric Assessment (MeSH), Humans (MeSH), Male (MeSH), Pneumococcal Vaccines (administration & dosage), Pneumonia, Pneumococcal (mortality), Pneumonia, Pneumococcal (prevention & control), Prevalence (MeSH), Primary Prevention (methods), Proportional Hazards Models (MeSH), Prospective Studies (MeSH), Severity of Illness Index (MeSH), Spain (epidemiology), Survival Analysis (MeSH), Vaccination (methods).
- MESH :
- chemical , administration & dosage : Pneumococcal Vaccines.
- geographic , epidemiology : Spain.
- methods : Primary Prevention, Vaccination.
- mortality : Community-Acquired Infections, Pneumonia, Pneumococcal.
- prevention & control : Community-Acquired Infections, Pneumonia, Pneumococcal.
- Age Factors, Aged, Aged, 80 and over, Analysis of Variance, Cohort Studies, Female, Geriatric Assessment, Humans, Male, Prevalence, Proportional Hazards Models, Prospective Studies, Severity of Illness Index, Survival Analysis.
Abstract
The present study assessed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine to prevent pneumonia and death in older adults in a first-time report between January and December 2002. A prospective cohort study was conducted including all individuals>or=65 yrs of age assigned to one of eight primary care centres in Tarragona, Spain (n=11,241). The primary outcomes were community-acquired pneumonia (hospitalised or outpatient) and death from pneumonia. All pneumonias were validated by checking clinical records. The association between the pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazard models, adjusted by age, sex, influenza vaccination status, comorbidity and immunological status. Pneumococcal vaccination did not alter the risk of hospitalisation from pneumonia (hazard ratio (HR): 0.80; 95% confidence interval (CI): 0.50-1.28) or overall pneumonia (HR: 0.86; 95% CI: 0.56-1.31), but the vaccine was associated with considerable reductions of death risk from pneumonia (HR: 0.28; 95% CI: 0.09-0.83). In conclusion, these results suggest that pneumococcal polysaccharide vaccine may not be effective in reducing the incidence of pneumonia, but may be able to diminish the severity of the infection. These findings support the effectiveness of the pneumococcal polysaccharide vaccine to prevent mortality caused by pneumonia in older adults, providing a new argument to recommend systematic vaccination in the elderly.
DOI: 10.1183/09031936.05.00030205
PubMed: 16319340
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.</title><author><name sortKey="Vila C Rcoles, A" sort="Vila C Rcoles, A" uniqKey="Vila C Rcoles A" first="A" last="Vila-C Rcoles">A. Vila-C Rcoles</name><affiliation wicri:level="2"><nlm:affiliation>EVAN-65 Group of Primary Care Service Tarragona-Valls, Institut Català de la Salut, Prat de la Riba 39, Tarragona 43001, Spain. avila.tarte.ics@gencat.net</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>EVAN-65 Group of Primary Care Service Tarragona-Valls, Institut Català de la Salut, Prat de la Riba 39, Tarragona 43001</wicri:regionArea><placeName><region nuts="2" type="communauté">Catalogne</region></placeName></affiliation></author><author><name sortKey="Ochoa Gondar, O" sort="Ochoa Gondar, O" uniqKey="Ochoa Gondar O" first="O" last="Ochoa-Gondar">O. Ochoa-Gondar</name></author><author><name sortKey="Llor, C" sort="Llor, C" uniqKey="Llor C" first="C" last="Llor">C. Llor</name></author><author><name sortKey="Hospital, I" sort="Hospital, I" uniqKey="Hospital I" first="I" last="Hospital">I. Hospital</name></author><author><name sortKey="Rodriguez, T" sort="Rodriguez, T" uniqKey="Rodriguez T" first="T" last="Rodríguez">T. Rodríguez</name></author><author><name sortKey="G Mez, A" sort="G Mez, A" uniqKey="G Mez A" first="A" last="G Mez">A. G Mez</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16319340</idno><idno type="pmid">16319340</idno><idno type="doi">10.1183/09031936.05.00030205</idno><idno type="wicri:Area/Main/Corpus">00612</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00612</idno><idno type="wicri:Area/Main/Curation">000612</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000612</idno><idno type="wicri:Area/Main/Exploration">000612</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.</title><author><name sortKey="Vila C Rcoles, A" sort="Vila C Rcoles, A" uniqKey="Vila C Rcoles A" first="A" last="Vila-C Rcoles">A. Vila-C Rcoles</name><affiliation wicri:level="2"><nlm:affiliation>EVAN-65 Group of Primary Care Service Tarragona-Valls, Institut Català de la Salut, Prat de la Riba 39, Tarragona 43001, Spain. avila.tarte.ics@gencat.net</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>EVAN-65 Group of Primary Care Service Tarragona-Valls, Institut Català de la Salut, Prat de la Riba 39, Tarragona 43001</wicri:regionArea><placeName><region nuts="2" type="communauté">Catalogne</region></placeName></affiliation></author><author><name sortKey="Ochoa Gondar, O" sort="Ochoa Gondar, O" uniqKey="Ochoa Gondar O" first="O" last="Ochoa-Gondar">O. Ochoa-Gondar</name></author><author><name sortKey="Llor, C" sort="Llor, C" uniqKey="Llor C" first="C" last="Llor">C. Llor</name></author><author><name sortKey="Hospital, I" sort="Hospital, I" uniqKey="Hospital I" first="I" last="Hospital">I. Hospital</name></author><author><name sortKey="Rodriguez, T" sort="Rodriguez, T" uniqKey="Rodriguez T" first="T" last="Rodríguez">T. Rodríguez</name></author><author><name sortKey="G Mez, A" sort="G Mez, A" uniqKey="G Mez A" first="A" last="G Mez">A. G Mez</name></author></analytic><series><title level="j">The European respiratory journal</title><idno type="ISSN">0903-1936</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Analysis of Variance (MeSH)</term><term>Cohort Studies (MeSH)</term><term>Community-Acquired Infections (mortality)</term><term>Community-Acquired Infections (prevention & control)</term><term>Female (MeSH)</term><term>Geriatric Assessment (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Pneumococcal Vaccines (administration & dosage)</term><term>Pneumonia, Pneumococcal (mortality)</term><term>Pneumonia, Pneumococcal (prevention & control)</term><term>Prevalence (MeSH)</term><term>Primary Prevention (methods)</term><term>Proportional Hazards Models (MeSH)</term><term>Prospective Studies (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Spain (epidemiology)</term><term>Survival Analysis (MeSH)</term><term>Vaccination (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie (MeSH)</term><term>Analyse de variance (MeSH)</term><term>Espagne (épidémiologie)</term><term>Facteurs âges (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections communautaires (mortalité)</term><term>Infections communautaires (prévention et contrôle)</term><term>Modèles des risques proportionnels (MeSH)</term><term>Mâle (MeSH)</term><term>Pneumonie à pneumocoques (mortalité)</term><term>Pneumonie à pneumocoques (prévention et contrôle)</term><term>Prévalence (MeSH)</term><term>Prévention primaire (méthodes)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccination (méthodes)</term><term>Vaccins antipneumococciques (administration et posologie)</term><term>Études de cohortes (MeSH)</term><term>Études prospectives (MeSH)</term><term>Évaluation gériatrique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Pneumococcal Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antipneumococciques</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Primary Prevention</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Community-Acquired Infections</term><term>Pneumonia, Pneumococcal</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections communautaires</term><term>Pneumonie à pneumocoques</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Prévention primaire</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Community-Acquired Infections</term><term>Pneumonia, Pneumococcal</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections communautaires</term><term>Pneumonie à pneumocoques</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Cohort Studies</term><term>Female</term><term>Geriatric Assessment</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Proportional Hazards Models</term><term>Prospective Studies</term><term>Severity of Illness Index</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term><term>Analyse de variance</term><term>Facteurs âges</term><term>Femelle</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Modèles des risques proportionnels</term><term>Mâle</term><term>Prévalence</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études de cohortes</term><term>Études prospectives</term><term>Évaluation gériatrique</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The present study assessed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine to prevent pneumonia and death in older adults in a first-time report between January and December 2002. A prospective cohort study was conducted including all individuals>or=65 yrs of age assigned to one of eight primary care centres in Tarragona, Spain (n=11,241). The primary outcomes were community-acquired pneumonia (hospitalised or outpatient) and death from pneumonia. All pneumonias were validated by checking clinical records. The association between the pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazard models, adjusted by age, sex, influenza vaccination status, comorbidity and immunological status. Pneumococcal vaccination did not alter the risk of hospitalisation from pneumonia (hazard ratio (HR): 0.80; 95% confidence interval (CI): 0.50-1.28) or overall pneumonia (HR: 0.86; 95% CI: 0.56-1.31), but the vaccine was associated with considerable reductions of death risk from pneumonia (HR: 0.28; 95% CI: 0.09-0.83). In conclusion, these results suggest that pneumococcal polysaccharide vaccine may not be effective in reducing the incidence of pneumonia, but may be able to diminish the severity of the infection. These findings support the effectiveness of the pneumococcal polysaccharide vaccine to prevent mortality caused by pneumonia in older adults, providing a new argument to recommend systematic vaccination in the elderly.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16319340</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0903-1936</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The European respiratory journal</Title><ISOAbbreviation>Eur. Respir. J.</ISOAbbreviation></Journal><ArticleTitle>Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.</ArticleTitle><Pagination><MedlinePgn>1086-91</MedlinePgn></Pagination><Abstract><AbstractText>The present study assessed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine to prevent pneumonia and death in older adults in a first-time report between January and December 2002. A prospective cohort study was conducted including all individuals>or=65 yrs of age assigned to one of eight primary care centres in Tarragona, Spain (n=11,241). The primary outcomes were community-acquired pneumonia (hospitalised or outpatient) and death from pneumonia. All pneumonias were validated by checking clinical records. The association between the pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazard models, adjusted by age, sex, influenza vaccination status, comorbidity and immunological status. Pneumococcal vaccination did not alter the risk of hospitalisation from pneumonia (hazard ratio (HR): 0.80; 95% confidence interval (CI): 0.50-1.28) or overall pneumonia (HR: 0.86; 95% CI: 0.56-1.31), but the vaccine was associated with considerable reductions of death risk from pneumonia (HR: 0.28; 95% CI: 0.09-0.83). In conclusion, these results suggest that pneumococcal polysaccharide vaccine may not be effective in reducing the incidence of pneumonia, but may be able to diminish the severity of the infection. These findings support the effectiveness of the pneumococcal polysaccharide vaccine to prevent mortality caused by pneumonia in older adults, providing a new argument to recommend systematic vaccination in the elderly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vila-Córcoles</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>EVAN-65 Group of Primary Care Service Tarragona-Valls, Institut Català de la Salut, Prat de la Riba 39, Tarragona 43001, Spain. avila.tarte.ics@gencat.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochoa-Gondar</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Llor</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hospital</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Rodríguez</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Gómez</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Respir J</MedlineTA><NlmUniqueID>8803460</NlmUniqueID><ISSNLinking>0903-1936</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022242">Pneumococcal Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Respir J. 2005 Dec;26(6):982-3</RefSource><PMID Version="1">16319323</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017714" MajorTopicYN="N">Community-Acquired Infections</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022242" MajorTopicYN="N">Pneumococcal Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011018" MajorTopicYN="N">Pneumonia, Pneumococcal</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011322" MajorTopicYN="N">Primary Prevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16319340</ArticleId><ArticleId IdType="pii">26/6/1086</ArticleId><ArticleId IdType="doi">10.1183/09031936.05.00030205</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region></list><tree><noCountry><name sortKey="G Mez, A" sort="G Mez, A" uniqKey="G Mez A" first="A" last="G Mez">A. G Mez</name><name sortKey="Hospital, I" sort="Hospital, I" uniqKey="Hospital I" first="I" last="Hospital">I. Hospital</name><name sortKey="Llor, C" sort="Llor, C" uniqKey="Llor C" first="C" last="Llor">C. Llor</name><name sortKey="Ochoa Gondar, O" sort="Ochoa Gondar, O" uniqKey="Ochoa Gondar O" first="O" last="Ochoa-Gondar">O. Ochoa-Gondar</name><name sortKey="Rodriguez, T" sort="Rodriguez, T" uniqKey="Rodriguez T" first="T" last="Rodríguez">T. Rodríguez</name></noCountry><country name="Espagne"><region name="Catalogne"><name sortKey="Vila C Rcoles, A" sort="Vila C Rcoles, A" uniqKey="Vila C Rcoles A" first="A" last="Vila-C Rcoles">A. Vila-C Rcoles</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000617 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000617 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16319340
|texte= Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16319340" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |